Darmiyan, Inc

Sway Innovation Co, based in Berkeley, CA, focuses on creating compostable alternatives to plastic using the natural polymers found in seaweed. Their products, including polybags and die cut handle bags, aim to harness the regenerative qualities of seaweed to provide sustainable packaging solutions. Embodying the principles of the circular economy, Sway emphasizes reducing waste, maintaining the use of materials, and regenerating ecological systems affected by climate change and plastic pollution. Their innovative approach is designed to benefit both social and environmental systems, making sustainable packaging accessible to a wide range of brands through partnerships with platforms like EcoEnclose. Generated from the website

AHEAD Medicine is revolutionizing flow cytometry analysis with its AI-powered Cyto-copilot, designed to enhance efficiency, consistency, and scalability in research, clinical diagnostics, and quality control for cell therapy. The technology enables automated analysis that is up to 100 times faster than manual methods, ensuring reproducible results while minimizing operator variability. The company has been recognized for its innovative contributions to medical technology, demonstrated through various accolades and collaborations, including participation in specialty conferences and partnerships with significant organizations. AHEAD Medicine continues to position itself as a leader in the field, driving advancements in AI and flow cytometry. Generated from the website

Xalud Therapeutics, Inc., based in Berkeley, CA, is a clinical-stage biotechnology company pioneering a non-viral plasmid DNA (pDNA) gene therapy platform aimed at addressing chronic inflammation by restoring immune system balance. Their lead candidate, XT-150, leverages a proprietary version of interleukin-10 (IL-10v) to target various conditions, including musculoskeletal and neurodegenerative diseases, with a focus on treating the root causes of inflammation rather than merely alleviating symptoms. The company's innovative approach promises adaptability and safety in delivering transgenes for a range of chronic inflammatory, neurological, and autoimmune disorders. Xalud is currently conducting clinical trials for XT-150, including a completed Phase 2b trial for osteoarthritis of the knee, while exploring diverse therapeutic applications through preclinical studies. Generated from the website